Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
Pharmabiz21h
US FDA accepts Gilead’s NDA for twice-yearly lenacapavir for HIV prevention under priority review
Foster City, California Thursday, February 20, 2025, 12:00 Hrs [IST] ...
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...
Le Lézard1d
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease
NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / Take a spin through the latest in Gilead's science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry ...
Daily1d
Gilead new drug applications for twice-yearly Lenacapavir for HIV Prevention accepted by USFDA under priority review
Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application ...
Fintel on MSN2d
Deutsche Bank Upgrades Gilead Sciences (GILD)
Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold ...
A new HIV prevention drug could get FDA approval this year
Preventing HIV infections could soon be as simple as two shots a year.
Gilead Gets FDA Priority Review of Twice-Yearly Shot to Prevent HIV
Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir the ...
FierceBiotech2d
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.